We’ve considered well over 650 ideas for new medical devices since our establishment. We’ve completed over 170 collaborative workshops and 100 R&D projects.
Our clients come from a range of professions: surgeons wanting to improve the lives of patients; researchers needing assistance to get their research out of the labs and into the hands of end-users; industry from startups to established businesses who are diversifying their product line; and the everyday inventor who sees a problem and has an idea to solve it.
Projects have included special glasses that help frequent flyers and shift workers adjust their sleep cycle, a cancer-detecting probe that is improving surgical outcomes and a device to assist orthopedic surgeons when fixing bone fractures.
Darius Chapman is founder and Managing Director of Cardiovascular Technology Services Pty Ltd, a bootstrapped medical device company selling products to major multinational companies and customers in an international market from Blackwood, South Australia. With a small and agile team of 2, CTS identifies small but important problems to help patients with cardiac electrical abnormalities.
Our company has been working on the development of a smart mechanical device to assist with rehabilitation following shoulder surgery. The device was created to allow passive shoulder ROM in the home or clinical setting, by driving the arm along a surface to allow safe mobilisation in the early stages of rehabilitation.
Designed by a Dental Hygienist to be the ultimate mouldable mouthguard. NeoMorph is a hybrid, combining the best qualities of the professionally made mouthguard with the convenience of a “boil & bite”. No more bulky, ill-fitting guards that dislodge on impact or bond to orthodontic appliances. NeoMorph is a pioneering over-the-counter sports mouthguard delivering a level of protection and custom fit previously unexpected in a reformable mouth guard.
Approximately 76,000 pregnant women and 500,000 babies die from pre-eclampsia across the world every year. Women in developing countries are seven times more likely to suffer from the condition due to delayed diagnosis and a lack of access to hospitals.
Causes of pre-eclampsia are not entirely understood, but if left untreated it can lead to blood clots, organ failure, and death. Rapid, affordable, and accurate diagnostic tools are therefore essential in aiding treatment.
Now, with the help of the Medical Device Partnering Program, a portable diagnostic device being developed by Professor Benjamin Thierry, Dr Duy Tran and a team from the University of South Australia’s Future Industries Institute (UniSA FII) has shown it could pose a solution.
What started as a family injury has turned into a rehabilitation game-changer receiving global attention.
The Prohab Connected Healthcare Device, the brainchild of physiotherapist Lyndon Huf, is an innovative rehabilitation device that accurately measures the force-generating capability of an individual’s muscle, in order to guide and personalise prescription of exercise and rehabilitation programs .
When Scott Blackburn injured himself badly in an accident, breaking both arms and his leg, he was surprised when the Ambulance arrived and treated him with a piece of cardboard.
Thinking there must be a better way, Scott established Fluoro Medical and created their first product, the CAS Splint. He then turned to the Medical Device Partnering Program (MDPP) for assistance to develop their new innovation.
The CAS Splint is an innovative, foldable splint for fractured limbs that requires no training to use and does not have to be removed during x-rays.
The MDPP undertook an end-user trial and survey to validate the current design of the splint and made recommendations for design modifications. The MDPP also provided a market intelligence report to Fluoro Medical.
When ResMed, a world-leading connected health company, engaged with the Medical Device Partnering Program in 2010, they wanted to investigate the feasibility of measuring specific signals from the head or face of a patient with Obstructive Sleep Apnoea (OSA).
ResMed sought to develop a non-intrusive device to monitor the cardiac health of OSA patients which would enable the monitoring of health so treatment could be administered with greater insight.
Obstructive Sleep Apnoea (OSA) is a condition where a person's upper airway becomes blocked during sleep and impacts more than 936 million people worldwide. Not only does OSA impact sleep quality, but patients are at a greater risk of developing cardiovascular disease and other heart problems.
The MDPP project resulted in a collaboration between ResMed and Flinders University, with a PhD scholarship funded to further research and development in this area.
When Orthopaedic Surgeon, Dr Matthew Liptak started noticing inconsistent outcomes in the rehabilitation of his patients after total knee replacement, he decided to take things into his own hands.
He identified a gap in the market for a simple and effective device to encourage, motivate and monitor the rehabilitation of his patients post-surgery.
Dr Liptak first approached the MDPP in 2013 for assistance with the development of Maxm Skate, a skate-like device which straps to a patient’s foot. Whilst he had an initial prototype of the skate, he needed R&D assistance to develop a sensor which would record the user’s range of movement.
Detecting cancer is set to become safer and more accurate with the development of a new cancer-detecting probe.
The probe, an invention of University of South Australia researchers Professor Benjamin Thierry and Dr Aidan Cousins, provides a non-radioactive alternative to map how cancer has disseminated through the body.
Following initial bench-top testing of the device, the team first partnered with the MDPP in 2013, seeking out electronic engineering expertise and advice from end users and commercial experts.
Since 1987, world-renowned sleep psychologists, Professor Leon Lack and Dr Helen Wright from Flinders University, have studied the effects of light on the human body clock.
Their work focused on circadian rhythms, the fluctuations in biological process occurring on a 24-hour basis in the body. Research determined that exposure to bright light can normalize the timing of the rhythms and assist with the treatment of insomnia, winter depression, jet-lag and shift work disorder.
The result of this extensive body of work was Re-Timer, glasses proven to re-time one’s body clock. The glasses shine glowing green-blue light into the eye of the wearer to help manipulate their production of melatonin — the hormone the body uses to induce sleep.
When Adelaide-based orthopaedics company, Austofix, wanted to fast track their invention to market, they partnered with the Medical Device Partnering Program to make it a reality.
The Ezy-Aim Electronic Distal Targeting System, was developed to provide surgeons with ‘an extra pair of eyes’ when inserting nails and screws to repair broken bones.
The technology allows surgeons to accurately judge the location of the implant inside the bone, removing the need for multiple X-rays when fixing bone fractures.
MDPP supported University of Adelaide researchers to bring a new cancer-detecting probe to clinical trial.
The device – an optical fibre probe - identifies cancerous tissue in real time by measuring pH levels of tissue, assisting surgeons to precisely remove cancerous tissue while sparing the healthy tissue surrounding it.
Dr Erik Schartner and Professor Mark Hutchinson, who developed the concept, came to MDPP after conducting extensive lab based testing, “We were missing a prototype to demonstrate how the probe would function in an operating theatre. That is where the MDPP came in and we were very happy with their work.”
Page 1 of 2